ArticleBladder (San Francisco, Calif.)2025
Comparative analysis of urinary antibiograms in community pediatric and geriatric populations in British Columbia, Canada.
Article in Bladder (San Francisco, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Clinical and Laboratory Standards Institute (CLSI) recommends the development of enhanced antibiograms specifically for elderly patients (≥65 years) to address the needs of long-term care facilities and to account for the anatomical sites from which specimens are collected, thereby facilitating antimicrobial stewardship. Similarly, the Canadian Pediatric Society advocates developing local, age-specific antibiograms to guide antimicrobial selection for targeted infections. Objective: This study aimed to develop antibiograms based on uropathogens identified at LifeLabs in British Columbia (BC), Canada. Methods: Urinary specimens from pediatric (<18 years) and geriatric (≥65 years) patients were collected and processed at LifeLabs, a community laboratory network comprising 129 collection centers across BC, between October 1, 2023, and September 30, 2024. Urinary antibiograms for both groups were developed in accordance with CLSI guidelines. Results: Among the 13,870 pediatric specimens, the most common uropathogen was Conclusion: The distribution of common uropathogens and their susceptibilities differed between pediatric and geriatric groups, supporting the need for age-specific antibiograms in community settings. Ciprofloxacin demonstrated lower susceptibility to the predominant uropathogens in elderly patients. Community antimicrobial stewardship teams should acknowledge these differences to better prioritize interventions tailored to each age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.